JP2020532545A5 - - Google Patents

Download PDF

Info

Publication number
JP2020532545A5
JP2020532545A5 JP2020512586A JP2020512586A JP2020532545A5 JP 2020532545 A5 JP2020532545 A5 JP 2020532545A5 JP 2020512586 A JP2020512586 A JP 2020512586A JP 2020512586 A JP2020512586 A JP 2020512586A JP 2020532545 A5 JP2020532545 A5 JP 2020532545A5
Authority
JP
Japan
Prior art keywords
alkyl
acceptable salt
compound according
heterocycloalkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020512586A
Other languages
English (en)
Japanese (ja)
Other versions
JP7257387B2 (ja
JP2020532545A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/048372 external-priority patent/WO2019046318A1/en
Publication of JP2020532545A publication Critical patent/JP2020532545A/ja
Publication of JP2020532545A5 publication Critical patent/JP2020532545A5/ja
Application granted granted Critical
Publication of JP7257387B2 publication Critical patent/JP7257387B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020512586A 2017-08-29 2018-08-28 スピロ環化合物並びにその作製及び使用方法 Active JP7257387B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762551721P 2017-08-29 2017-08-29
US62/551,721 2017-08-29
PCT/US2018/048372 WO2019046318A1 (en) 2017-08-29 2018-08-28 SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF

Publications (3)

Publication Number Publication Date
JP2020532545A JP2020532545A (ja) 2020-11-12
JP2020532545A5 true JP2020532545A5 (enExample) 2021-10-07
JP7257387B2 JP7257387B2 (ja) 2023-04-13

Family

ID=65527860

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020512586A Active JP7257387B2 (ja) 2017-08-29 2018-08-28 スピロ環化合物並びにその作製及び使用方法

Country Status (27)

Country Link
US (1) US11142526B2 (enExample)
EP (1) EP3675847B1 (enExample)
JP (1) JP7257387B2 (enExample)
KR (1) KR20200046061A (enExample)
CN (1) CN111050765B (enExample)
AU (1) AU2018323459A1 (enExample)
BR (1) BR112020004101A2 (enExample)
CA (1) CA3072923A1 (enExample)
CL (1) CL2020000462A1 (enExample)
CO (1) CO2020001724A2 (enExample)
CR (1) CR20200089A (enExample)
DO (1) DOP2020000039A (enExample)
EA (1) EA202090312A1 (enExample)
EC (1) ECSP20013337A (enExample)
ES (1) ES2952332T3 (enExample)
GE (2) GEP20217327B (enExample)
IL (1) IL272580B (enExample)
JO (1) JOP20200023A1 (enExample)
MA (1) MA50041A (enExample)
MX (1) MX2020002251A (enExample)
NI (1) NI202000014A (enExample)
PE (1) PE20200664A1 (enExample)
PH (1) PH12020500372A1 (enExample)
SG (1) SG11202001022TA (enExample)
UA (1) UA126685C2 (enExample)
WO (1) WO2019046318A1 (enExample)
ZA (1) ZA202001208B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2800565T1 (sl) 2012-01-06 2020-10-30 Lundbeck La Jolla Research Center, Inc. Karbamatne spojine in metode izdelave in uporabe le-teh
EP3455226B1 (en) 2016-05-12 2020-12-30 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
PE20200664A1 (es) 2017-08-29 2020-06-11 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso
BR112020003946A2 (pt) 2017-08-29 2020-09-08 Lundbeck La Jolla Research Center, Inc. compostos de espirociclo e métodos para produzir e usar os mesmos
KR20220034104A (ko) * 2019-07-09 2022-03-17 에프. 호프만-라 로슈 아게 신규 헤테로고리 화합물
CN116096723A (zh) * 2020-08-26 2023-05-09 豪夫迈·罗氏有限公司 用作magl抑制剂的杂环化合物
UY39516A (es) 2020-11-13 2022-05-31 H Lundbeck As Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión
JP7777891B2 (ja) 2021-12-29 2025-12-01 サイ セラピューティクス インコーポレイテッド モノアシルグリセロールリパーゼ(magl)の阻害
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태
EP4665718A1 (en) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2440803A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
WO2009111550A1 (en) 2008-03-05 2009-09-11 Targacept, Inc. Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
CN102575076B (zh) 2009-09-29 2014-08-20 普立万公司 具有模拟金属或珠光外观的聚酯制品
CA2778484C (en) 2009-10-23 2018-07-31 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US9108937B2 (en) 2010-03-04 2015-08-18 Merck Sharp & Dohme Corp. Positive allosteric modulators of mGluR2
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
SI2800565T1 (sl) 2012-01-06 2020-10-30 Lundbeck La Jolla Research Center, Inc. Karbamatne spojine in metode izdelave in uporabe le-teh
DK2900669T3 (da) 2012-09-25 2019-11-04 Hoffmann La Roche Hexahydropyrrolo[3,4-C]pyrrolderivater og relaterede forbindelser som autotaxin (ATX)-inhibitorer og som inhibitorer af lysophosphatidsyre (LPA)-produktion til behandling af f.eks. nyresygdomme
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター,インク. ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
US10093630B2 (en) * 2014-05-21 2018-10-09 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
EP3271352B1 (en) 2015-03-18 2021-05-12 H. Lundbeck A/S Piperazine carbamates and methods of making and using same
EA035823B1 (ru) 2015-07-31 2020-08-17 Пфайзер Инк. 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl
WO2017087858A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
TWI738753B (zh) 2016-03-31 2021-09-11 日商武田藥品工業股份有限公司 雜環化合物
EP3455226B1 (en) 2016-05-12 2020-12-30 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
JOP20190050A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
AU2017361254B2 (en) 2016-11-16 2021-09-23 H. Lundbeck A/S. Pharmaceutical formulations
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
KR102508739B1 (ko) 2016-11-16 2023-03-09 하. 룬드벡 아크티에셀스카브 Magl 억제제의 결정형
PE20200664A1 (es) 2017-08-29 2020-06-11 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso
BR112020003946A2 (pt) 2017-08-29 2020-09-08 Lundbeck La Jolla Research Center, Inc. compostos de espirociclo e métodos para produzir e usar os mesmos

Similar Documents

Publication Publication Date Title
JP2020532545A5 (enExample)
JP2020532547A5 (enExample)
JP2020529994A5 (enExample)
JP2019524883A5 (enExample)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2020169171A5 (enExample)
JP2016518328A5 (enExample)
JP2017530959A5 (enExample)
JP2018536634A5 (enExample)
JP2019034943A5 (enExample)
JP2019531279A5 (enExample)
JP2018510139A5 (enExample)
JP2016531126A5 (enExample)
JP2017526674A5 (enExample)
JP2016530259A5 (enExample)
JP2015520140A5 (enExample)
JP2010511721A5 (enExample)
RU2016137181A (ru) Противофиброзные пиридиноны
JP2017523225A5 (enExample)
JP2013507425A5 (enExample)
JP2016517851A5 (enExample)
JP2016518437A5 (enExample)
JP2020502047A5 (enExample)
JP2011513410A5 (enExample)
JP2017506666A5 (enExample)